EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
01 2020
Historique:
received: 10 05 2019
revised: 07 06 2019
accepted: 07 06 2019
pubmed: 24 6 2019
medline: 21 4 2020
entrez: 24 6 2019
Statut: ppublish

Résumé

Tremendous opportunities for health research have been unlocked by the recent expansion of big data and artificial intelligence. However, this is an emergent area where recommendations for optimal use and implementation are needed. The objective of these European League Against Rheumatism (EULAR) points to consider is to guide the collection, analysis and use of big data in rheumatic and musculoskeletal disorders (RMDs). A multidisciplinary task force of 14 international experts was assembled with expertise from a range of disciplines including computer science and artificial intelligence. Based on a literature review of the current status of big data in RMDs and in other fields of medicine, points to consider were formulated. Levels of evidence and strengths of recommendations were allocated and mean levels of agreement of the task force members were calculated. Three overarching principles and 10 points to consider were formulated. The overarching principles address ethical and general principles for dealing with big data in RMDs. The points to consider cover aspects of data sources and data collection, privacy by design, data platforms, data sharing and data analyses, in particular through artificial intelligence and machine learning. Furthermore, the points to consider state that big data is a moving field in need of adequate reporting of methods and benchmarking, careful data interpretation and implementation in clinical practice. These EULAR points to consider discuss essential issues and provide a framework for the use of big data in RMDs.

Sections du résumé

BACKGROUND
Tremendous opportunities for health research have been unlocked by the recent expansion of big data and artificial intelligence. However, this is an emergent area where recommendations for optimal use and implementation are needed. The objective of these European League Against Rheumatism (EULAR) points to consider is to guide the collection, analysis and use of big data in rheumatic and musculoskeletal disorders (RMDs).
METHODS
A multidisciplinary task force of 14 international experts was assembled with expertise from a range of disciplines including computer science and artificial intelligence. Based on a literature review of the current status of big data in RMDs and in other fields of medicine, points to consider were formulated. Levels of evidence and strengths of recommendations were allocated and mean levels of agreement of the task force members were calculated.
RESULTS
Three overarching principles and 10 points to consider were formulated. The overarching principles address ethical and general principles for dealing with big data in RMDs. The points to consider cover aspects of data sources and data collection, privacy by design, data platforms, data sharing and data analyses, in particular through artificial intelligence and machine learning. Furthermore, the points to consider state that big data is a moving field in need of adequate reporting of methods and benchmarking, careful data interpretation and implementation in clinical practice.
CONCLUSION
These EULAR points to consider discuss essential issues and provide a framework for the use of big data in RMDs.

Identifiants

pubmed: 31229952
pii: annrheumdis-2019-215694
doi: 10.1136/annrheumdis-2019-215694
doi:

Types de publication

Consensus Development Conference Guideline Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-76

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: LG has published a study for which Orange IMT (telecommunications company) performed machine-learning analyses, without charge to the author. HS is an employee of Sanoïa, Digital CRO providing clinical research services including data science. RC is an employee of Orange Healthcare. There are no competing interests for the other authors.

Auteurs

Laure Gossec (L)

Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France laure.gossec@gmail.com.
APHP, Rheumatology Department, Pitie Salpetriere Hospital, Paris, France.

Joanna Kedra (J)

Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.
APHP, Rheumatology Department, Pitie Salpetriere Hospital, Paris, France.

Hervé Servy (H)

Sanoïa, e-Health services, Gardanne, France.

Aridaman Pandit (A)

Dept of Rheumatology, Clinical Immunology and Laboratory of Translational Immunology, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.

Simon Stones (S)

School of Healthcare, University of Leeds, Leeds, UK.

Francis Berenbaum (F)

Rheumatology, St Antoine Hospital, Sorbonne Université, INSERM, Paris, France.

Axel Finckh (A)

Division of Rheumatology, University of Geneva, Geneva, Switzerland.

Xenofon Baraliakos (X)

Rheumazentrum Ruhrgebiet Sankt Josefs-Krankenhaus, Herne, Germany.
Ruhr-Universitat Bochum, Bochum, Germany.

Tanja A Stamm (TA)

Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

David Gomez-Cabrero (D)

Translational Bioinformatics Unit, Navarra Biomed, Departamento de Salud-Universidad Públicade Navarra, Pamplona, Navarra, Spain.

Christian Pristipino (C)

Ospedale San Filippo Neri, Rome, Italy.

Remy Choquet (R)

Orange Healthcare, INSERM U1142, Paris, France.

Gerd R Burmester (GR)

Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany.

Timothy R D J Radstake (TRDJ)

Dept of Rheumatology, Clinical Immunology and Laboratory of Translational Immunology, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH